MetaCap

Jyong Biotech (MENS) vs MacroGenics (MGNX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MacroGenics (MGNX) has outperformed Jyong Biotech (MENS) over the past year, gaining 40.0% versus a loss of 95.3%. MacroGenics is the larger company by market cap ($125.3 million vs $110.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MENS-95.28%MGNX+40.00%
+264%+76%-112%
Nov 21, 20251 yearNov 20, 2026
MENS-81.90%MGNX+49.62%
+759%+319%-122%
Jun 16, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MENS versus MGNX key metrics
MetricMENSMGNX
Share price$1.45$1.96
Market cap$110.24M$125.26M
1-day change-17.14%-1.01%
YTD return-63.29%+21.74%
1-year return-95.28%+40.00%
5-year return—-89.56%
EPS (TTM)$-0.06$-2.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$149.50M
Revenue growth (YoY)—-0.31%
Net income (latest FY)$-4.67M$-74.62M
Gross margin—100.00%
Operating margin—-48.72%
Net margin—-49.91%
52-week high$38.88$5.08
52-week low$1.43$1.32
Distance from 52-week high-96.27%-61.42%
Analyst consensus—buy
Avg. price target upside—+308.16%
Average volume44.23K747.02K
Shares outstanding74.23M63.91M
Employees27293
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MGNX has outperformed MENS by 135.3 percentage points over the past year.

About Jyong Biotech

MENS stock →

Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees

About MacroGenics

MGNX stock →

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.

Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees

MENS vs MGNX FAQ

Which is bigger, Jyong Biotech or MacroGenics?

MacroGenics (MGNX) is larger, with a market capitalization of $125.26M compared with $110.24M for Jyong Biotech (MENS).

Which stock has performed better over the past year, MENS or MGNX?

MGNX returned +40.00% over the past 12 months, compared with -95.28% for MENS (price return, excluding dividends). Past performance does not predict future results.

Are Jyong Biotech and MacroGenics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons